Market watch: Upcoming market catalysts in Q4 2013 – Nature.com
Market watch: Upcoming market catalysts in Q4 2013Nature.comSubsequently, data from the second stage of the trial comparing obinutuzumab head-to-head against rituximab, which were both in combination with chlorambucil, demonstrated a significant improv…
